Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging

Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and ra...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Moramkar, Nimish [verfasserIn] Bhatt, Purvi [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	Chitosan derivatives Chitosan nanoparticles Chitosan nanocomplexes Drug delivery Cancer, optical imaging

Übergeordnetes Werk:	Enthalten in: European polymer journal - New York, NY [u.a.] : Elsevier, 1965, 154
Übergeordnetes Werk:	volume:154

DOI / URN:	10.1016/j.eurpolymj.2021.110540

Katalog-ID:	ELV006202462

Internformat


LEADER	01000caa a22002652 4500
001	ELV006202462
003	DE-627
005	20231205154444.0
007	cr uuu---uuuuu
008	230505s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.eurpolymj.2021.110540 \|2 doi
035			\|a (DE-627)ELV006202462
035			\|a (ELSEVIER)S0014-3057(21)00274-3
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
082	0	4	\|a 670 \|q DE-600
084			\|a 35.80 \|2 bkl
100	1		\|a Moramkar, Nimish \|e verfasserin \|0 (orcid)0000-0002-0227-9856 \|4 aut
245	1	0	\|a Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging
264		1	\|c 2021
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery.
650		4	\|a Chitosan derivatives
650		4	\|a Chitosan nanoparticles
650		4	\|a Chitosan nanocomplexes
650		4	\|a Drug delivery
650		4	\|a Cancer, optical imaging
700	1		\|a Bhatt, Purvi \|e verfasserin \|0 (orcid)0000-0001-8142-8284 \|4 aut
773	0	8	\|i Enthalten in \|t European polymer journal \|d New York, NY [u.a.] : Elsevier, 1965 \|g 154 \|h Online-Ressource \|w (DE-627)300897375 \|w (DE-600)1483529-0 \|w (DE-576)259270830 \|7 nnns
773	1	8	\|g volume:154
912			\|a GBV_USEFLAG_U
912			\|a SYSFLAG_U
912			\|a GBV_ELV
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_224
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2411
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
936	b	k	\|a 35.80 \|j Makromolekulare Chemie
951			\|a AR
952			\|d 154

Indexfelder

author_variant	n m nm p b pb
matchkey_str	moramkarnimishbhattpurvi:2021----:nihitcioadrvdaohrpuisoatcned
hierarchy_sort_str	2021
bklnumber	35.80
publishDate	2021
allfields	10.1016/j.eurpolymj.2021.110540 doi (DE-627)ELV006202462 (ELSEVIER)S0014-3057(21)00274-3 DE-627 ger DE-627 rda eng 670 DE-600 35.80 bkl Moramkar, Nimish verfasserin (orcid)0000-0002-0227-9856 aut Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery. Chitosan derivatives Chitosan nanoparticles Chitosan nanocomplexes Drug delivery Cancer, optical imaging Bhatt, Purvi verfasserin (orcid)0000-0001-8142-8284 aut Enthalten in European polymer journal New York, NY [u.a.] : Elsevier, 1965 154 Online-Ressource (DE-627)300897375 (DE-600)1483529-0 (DE-576)259270830 nnns volume:154 GBV_USEFLAG_U SYSFLAG_U GBV_ELV GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2411 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.80 Makromolekulare Chemie AR 154
spelling	10.1016/j.eurpolymj.2021.110540 doi (DE-627)ELV006202462 (ELSEVIER)S0014-3057(21)00274-3 DE-627 ger DE-627 rda eng 670 DE-600 35.80 bkl Moramkar, Nimish verfasserin (orcid)0000-0002-0227-9856 aut Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery. Chitosan derivatives Chitosan nanoparticles Chitosan nanocomplexes Drug delivery Cancer, optical imaging Bhatt, Purvi verfasserin (orcid)0000-0001-8142-8284 aut Enthalten in European polymer journal New York, NY [u.a.] : Elsevier, 1965 154 Online-Ressource (DE-627)300897375 (DE-600)1483529-0 (DE-576)259270830 nnns volume:154 GBV_USEFLAG_U SYSFLAG_U GBV_ELV GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2411 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.80 Makromolekulare Chemie AR 154
allfields_unstemmed	10.1016/j.eurpolymj.2021.110540 doi (DE-627)ELV006202462 (ELSEVIER)S0014-3057(21)00274-3 DE-627 ger DE-627 rda eng 670 DE-600 35.80 bkl Moramkar, Nimish verfasserin (orcid)0000-0002-0227-9856 aut Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery. Chitosan derivatives Chitosan nanoparticles Chitosan nanocomplexes Drug delivery Cancer, optical imaging Bhatt, Purvi verfasserin (orcid)0000-0001-8142-8284 aut Enthalten in European polymer journal New York, NY [u.a.] : Elsevier, 1965 154 Online-Ressource (DE-627)300897375 (DE-600)1483529-0 (DE-576)259270830 nnns volume:154 GBV_USEFLAG_U SYSFLAG_U GBV_ELV GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2411 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.80 Makromolekulare Chemie AR 154
allfieldsGer	10.1016/j.eurpolymj.2021.110540 doi (DE-627)ELV006202462 (ELSEVIER)S0014-3057(21)00274-3 DE-627 ger DE-627 rda eng 670 DE-600 35.80 bkl Moramkar, Nimish verfasserin (orcid)0000-0002-0227-9856 aut Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery. Chitosan derivatives Chitosan nanoparticles Chitosan nanocomplexes Drug delivery Cancer, optical imaging Bhatt, Purvi verfasserin (orcid)0000-0001-8142-8284 aut Enthalten in European polymer journal New York, NY [u.a.] : Elsevier, 1965 154 Online-Ressource (DE-627)300897375 (DE-600)1483529-0 (DE-576)259270830 nnns volume:154 GBV_USEFLAG_U SYSFLAG_U GBV_ELV GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2411 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.80 Makromolekulare Chemie AR 154
allfieldsSound	10.1016/j.eurpolymj.2021.110540 doi (DE-627)ELV006202462 (ELSEVIER)S0014-3057(21)00274-3 DE-627 ger DE-627 rda eng 670 DE-600 35.80 bkl Moramkar, Nimish verfasserin (orcid)0000-0002-0227-9856 aut Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery. Chitosan derivatives Chitosan nanoparticles Chitosan nanocomplexes Drug delivery Cancer, optical imaging Bhatt, Purvi verfasserin (orcid)0000-0001-8142-8284 aut Enthalten in European polymer journal New York, NY [u.a.] : Elsevier, 1965 154 Online-Ressource (DE-627)300897375 (DE-600)1483529-0 (DE-576)259270830 nnns volume:154 GBV_USEFLAG_U SYSFLAG_U GBV_ELV GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2411 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.80 Makromolekulare Chemie AR 154
language	English
source	Enthalten in European polymer journal 154 volume:154
sourceStr	Enthalten in European polymer journal 154 volume:154
format_phy_str_mv	Article
bklname	Makromolekulare Chemie
institution	findex.gbv.de
topic_facet	Chitosan derivatives Chitosan nanoparticles Chitosan nanocomplexes Drug delivery Cancer, optical imaging
dewey-raw	670
isfreeaccess_bool	false
container_title	European polymer journal
authorswithroles_txt_mv	Moramkar, Nimish @@aut@@ Bhatt, Purvi @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	300897375
dewey-sort	3670
id	ELV006202462
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV006202462</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20231205154444.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230505s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.eurpolymj.2021.110540</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV006202462</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0014-3057(21)00274-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">670</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Moramkar, Nimish</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-0227-9856</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chitosan derivatives</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chitosan nanoparticles</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chitosan nanocomplexes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug delivery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer, optical imaging</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bhatt, Purvi</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0001-8142-8284</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">European polymer journal</subfield><subfield code="d">New York, NY [u.a.] : Elsevier, 1965</subfield><subfield code="g">154</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)300897375</subfield><subfield code="w">(DE-600)1483529-0</subfield><subfield code="w">(DE-576)259270830</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:154</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2411</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.80</subfield><subfield code="j">Makromolekulare Chemie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">154</subfield></datafield></record></collection>
author	Moramkar, Nimish
spellingShingle	Moramkar, Nimish ddc 670 bkl 35.80 misc Chitosan derivatives misc Chitosan nanoparticles misc Chitosan nanocomplexes misc Drug delivery misc Cancer, optical imaging Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging
authorStr	Moramkar, Nimish
ppnlink_with_tag_str_mv	@@773@@(DE-627)300897375
format	electronic Article
dewey-ones	670 - Manufacturing
delete_txt_mv	keep
author_role	aut aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
topic_title	670 DE-600 35.80 bkl Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging Chitosan derivatives Chitosan nanoparticles Chitosan nanocomplexes Drug delivery Cancer, optical imaging
topic	ddc 670 bkl 35.80 misc Chitosan derivatives misc Chitosan nanoparticles misc Chitosan nanocomplexes misc Drug delivery misc Cancer, optical imaging
topic_unstemmed	ddc 670 bkl 35.80 misc Chitosan derivatives misc Chitosan nanoparticles misc Chitosan nanocomplexes misc Drug delivery misc Cancer, optical imaging
topic_browse	ddc 670 bkl 35.80 misc Chitosan derivatives misc Chitosan nanoparticles misc Chitosan nanocomplexes misc Drug delivery misc Cancer, optical imaging
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	European polymer journal
hierarchy_parent_id	300897375
dewey-tens	670 - Manufacturing
hierarchy_top_title	European polymer journal
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)300897375 (DE-600)1483529-0 (DE-576)259270830
title	Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging
ctrlnum	(DE-627)ELV006202462 (ELSEVIER)S0014-3057(21)00274-3
title_full	Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging
author_sort	Moramkar, Nimish
journal	European polymer journal
journalStr	European polymer journal
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2021
contenttype_str_mv	zzz
author_browse	Moramkar, Nimish Bhatt, Purvi
container_volume	154
class	670 DE-600 35.80 bkl
format_se	Elektronische Aufsätze
author-letter	Moramkar, Nimish
doi_str_mv	10.1016/j.eurpolymj.2021.110540
normlink	(ORCID)0000-0002-0227-9856 (ORCID)0000-0001-8142-8284
normlink_prefix_str_mv	(orcid)0000-0002-0227-9856 (orcid)0000-0001-8142-8284
dewey-full	670
author2-role	verfasserin
title_sort	insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging
title_auth	Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging
abstract	Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery.
abstractGer	Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery.
abstract_unstemmed	Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery.
collection_details	GBV_USEFLAG_U SYSFLAG_U GBV_ELV GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2411 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393
title_short	Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging
remote_bool	true
author2	Bhatt, Purvi
author2Str	Bhatt, Purvi
ppnlink	300897375
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1016/j.eurpolymj.2021.110540
up_date	2024-07-06T20:34:27.720Z
_version_	1803863266659663872
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV006202462</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20231205154444.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230505s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.eurpolymj.2021.110540</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV006202462</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0014-3057(21)00274-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">670</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Moramkar, Nimish</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-0227-9856</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cancer is a multifactorial, unpredictable chronic ailment with an anarchical, uncontrolled cell proliferation and globally is one of the leading causes of mortality and morbidity owing to limitations in effectual theranostics (detection and therapy). Current treatment modalities include chemo and radiation therapy, surgery and targeted therapies which are expensive and often accompanied by undesirable outcomes. Nanotechnology has remarkably and briskly emerged in the past few decades and developed target specific drug carriers for delivery of therapeutic molecules for tumor theranostics. Chitosan (CS) based nanocomplexes have synergistically evolved as potential drug delivery vectors with biocompatibility, biodegradability, negligible toxicity, structural changeability and used to dispatch therapeutic agents to tumor cells via targeted approach and help evade issues challenged by drug delivery thereby ameliorating treatment efficiency. This review provides insight into physicochemical attributes of CS derivatives, compares their advantages/ limitations and use of CS-based derivatives for their diverse biomedical and pharmaceutical applications such as cancer diagnosis, imaging, photodynamic therapy and drug/nano-vaccine delivery.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chitosan derivatives</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chitosan nanoparticles</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chitosan nanocomplexes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug delivery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer, optical imaging</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bhatt, Purvi</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0001-8142-8284</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">European polymer journal</subfield><subfield code="d">New York, NY [u.a.] : Elsevier, 1965</subfield><subfield code="g">154</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)300897375</subfield><subfield code="w">(DE-600)1483529-0</subfield><subfield code="w">(DE-576)259270830</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:154</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2411</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.80</subfield><subfield code="j">Makromolekulare Chemie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">154</subfield></datafield></record></collection>
score	7.400571

Nicht das Richtige dabei?

Schreiben Sie uns!

Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?